Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll Dosing 6-thioguanine in inflammatory bowel disease: expert-based guidelines for daily practice Seinen ML; van Asseldonk DP; Mulder CJ; de Boer NKJ Gastrointestin Liver Dis 2010[Sep]; 19 (3): 291-4Conventional thiopurines are considered to be effective and safe in the treatment of inflammatory bowel disease (IBD) patients; unfortunately more than 50% of patients discontinue thiopurine therapy, mainly due to the development of intractable adverse events. In recent years, the use of 6-thioguanine has been proposed as an alternative thiopurine in IBD patients failing to tolerate or to respond to conventional thiopurine therapy. In this clinical review, we describe the rationale for 6-thioguanine therapy and discuss the reported hepatotoxicity of 6-thioguanine (especially nodular regenerative hyperplasia). We propose expert-based guidelines for balanced treatment.|Anti-Inflammatory Agents/*administration & dosage/adverse effects[MESH]|Chemical and Drug Induced Liver Injury/etiology[MESH]|Drug Monitoring[MESH]|Evidence-Based Medicine[MESH]|Gastrointestinal Agents/*administration & dosage/adverse effects[MESH]|Humans[MESH]|Inflammatory Bowel Diseases/*drug therapy[MESH]|Practice Guidelines as Topic[MESH]|Risk Assessment[MESH]|Thioguanine/*administration & dosage/adverse effects[MESH]|Treatment Outcome[MESH] |